The lifestyle layer that makes GLP-1 therapy work
Better adherence, preserved muscle and a supported off-ramp, with clinician sign-off on every plan change and outcomes reported back to the payer.
Payers are spending heavily on GLP-1s and not keeping the results
members remain on GLP-1 treatment after three years
of large US employers rate managing GLP-1 costs as extremely or very important
after stopping, plus lean-muscle loss during treatment, with little structured support
Sources: Prime Therapeutics data, cited by Mercer, “GLP-1 considerations for 2026”; Mercer employer survey.
As drug prices fall, value moves to the program around the drug
Prices are falling
US agreements cut GLP-1 prices from over $1,000 to as low as $245 a month for eligible patients, and oral options are arriving.
Payers want lifestyle support
Employers and plans increasingly tie coverage to lifestyle and behavioral programs.
Medicare is paying for outcomes
The CMS ACCESS Model pays for technology-enabled care tied to outcomes in chronic conditions.
Sources: IQVIA, “Outlook for Obesity in 2026”; MedCity News, Jan 2026; AAMC on the CMS ACCESS Model.
One program across the whole GLP-1 journey
Baseline and onboarding
Body composition, activity, nutrition and gut-health baseline, plus a side-effect plan.
Adherence and muscle
Protein and strength targets, GI side-effect support and early flags for drop-off.
Supported step-down
A structured taper with the prescriber, and habits that hold the results.
A licensed clinician reviews and signs off every plan change. Activity comes from a wearable, the phone or a weekly check-in; nutrition and gut health come from LIWEL’s own nutrition engine.
Prescribing stays with the member’s own clinician.The payer sees what its GLP-1 spend is buying
Reported per cohort to the employer or plan, de-identified, every quarter.
| Outcome | What we measure | Why the payer cares |
|---|---|---|
| Adherence | Months on therapy; drop-off flags acted on | Value from each fill |
| Muscle preservation | Lean-mass trend, strength and activity | Healthier weight loss |
| Side effects | GI symptoms logged and resolved | Fewer early stops |
| Off-ramp | Weight held after step-down | Lower long-term drug cost |
Outcome definitions and targets are agreed with each buyer. LIWEL has no US results yet; the first pilot is planned for 2027.
We measure what keeps the results
Measured muscle preservation
Lean mass and strength tracked, not just the scale.
Gut and side-effect support
Gut-health data and nutrition guidance to keep members on therapy.
A structured off-ramp
Step-down with the prescriber, monitored afterwards.
Clinician sign-off, one record
With or without a wearable: one record, every change approved.
Paid per member, with part of the fee tied to outcomes
Self-insured employers
A per-member-per-month fee, with a share at risk on adherence and outcomes.
Health plans, PBMs and obesity practices
The program as a condition of coverage, or white-labelled for prescribers.
Medicare and cash-pay members
Outcome-based Medicare models, and direct subscriptions.
Two tracks to evidence in 2027
Employer pilot
About 100–200 members on GLP-1s for six months with a launch employer. Readouts: adherence at 3 and 6 months, lean-mass trend, side-effect resolution and member experience, reported by data tier.
Randomized study
Standard care vs LIWEL, with lean mass measured by DEXA, testing early-signal hypotheses. Starts after the MVP.
The clinical team signs off the no-device pathway: a weekly check-in of about two minutes and a validated home strength test.
Pilot and study size, partners, states and dates are planning assumptions, to be confirmed.
Clinical, technical and healthcare leadership
Neela
Serial founder with 20+ years of GCC leadership at Cisco, Juniper and Epicor.
Pankaja Shankar
Leads the core AI and predictive engine.
Dr. Chithra Ram
Neuroradiologist; fellowship in neuroradiology at Duke.
Giri Chenji
Former CTO, Immuneel; Deloitte Health (US).
Gut-health data
Orcasho, licensed data partner by API (terms to be signed). Nutrition engine built in-house.
Platform development
Nisarga En-Tech, India, under development and licence agreements.
Finance & legal
US fractional CFO · Sathish Srinivasan, Legal Counsel
We’re hiring
GTM lead, Platform Architect, and a US obesity-medicine physician advisor.
Let’s design a pilot together
We’re looking to talk with organizations that want their GLP-1 spend to deliver results that last.
- Self-insured employers and benefits consultants
- Obesity-medicine physicians
- Health plans and PBMs
- Investors backing the US pilot